Danish pharmaceutical giant Novo Nordisk deepens its AI integration through a new collaboration with Anthropic, aiming to expedite early-stage drug development and stay ahead in a competitive market, despite cautious investor sentiment.
Novo Nordisk is deepening its push into artificial intelligence with a new partnership with Anthropic, in a move aimed at speeding up drug discovery and helping scientists work through the increasingly complex early stages of research and development. According to reports from Euronews and other industry outlets, the Danish drugmaker will test Anthropic’s Claude Science model across a range of R&D tasks as it looks for ways to shorten the path from laboratory ideas to new medicines.
The agreement comes as Novo Nordisk faces intensifying competition in obesity and diabetes, where it has built its reputation through blockbuster treatments such as Wegovy and Ozempic. The company has been trying to broaden its pipeline beyond those products, with CagriSema among the closely watched candidates. The experimental therapy combines semaglutide, already used in several Novo drugs, with cagrilintide, a compound linked to amylin-based treatments.
Novo said the collaboration is intended to help its researchers handle large volumes of scientific information and complex data more efficiently. Industry reports say the company is particularly interested in using AI for biological reasoning and for software tools that can support scientific workflows, rather than replacing researchers outright. The goal is to reduce the time spent on repetitive analysis and direct attention towards the most promising compounds and hypotheses.
The move also reflects a broader shift across pharmaceuticals, where companies are using AI to accelerate the earliest and often slowest parts of drug development. Anthropic is not the only technology partner being pulled into the sector. Eli Lilly has already announced a joint lab with Nvidia focused on AI-enabled drug discovery, with plans that could involve investment of up to $1 billion over five years. Moderna, too, has worked with OpenAI on a range of internal processes spanning research, clinical operations and business functions.
Novo’s announcement comes with a busy scientific calendar. The company said it will present 44 research abstracts at a European diabetes meeting later this month, underscoring how much of its near-term strategy still depends on execution in obesity and diabetes even as it expands its digital toolkit.
Investors have remained cautious. Novo shares were slightly lower in pre-market trading when the report was prepared, and the stock has fallen by more than 16% since the start of the year. At the same time, retail sentiment has turned more active, with data from Stocktwits showing a rise in discussion around the shares in the past day. For Novo, the Anthropic deal is both a technology bet and a signal that the company is trying to stay ahead in a fast-moving market where drug development speed now matters as much as scientific ambition.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
